GlobeNewswire

Tatung Launches IRIS – An AI-Powered Smart Wi-Fi Extender

Del

Quantenna high performance Mesh Wi-Fi rides the waves to new era of smart home applications via voice command

COLOGNE, Germany, June 04, 2019 (GLOBE NEWSWIRE) -- (ANGA COM 2019) -- Quantenna Communications (NASDAQ: QTNA), a global leader and innovator of high performance Wi-Fi solutions, and Tatung Technology Inc. (TTI), a leader in digital IP set-top box solutions for Tier 1 service providers and the IPTV industry, announced today the launch of IRIS SMC-5550 portable smart Mesh Wi-Fi extender. Based on Quantenna’s Spartan architecture, the all-in-one IRIS serves as a Mesh extender, a voice-controlled smart home hub and a Bluetooth speaker. IRIS allows service providers to deliver whole home coverage with superior Wi-Fi performance, while enabling emerging smart home IoT applications.

The number of connected devices for smart home applications is growing exponentially driving the demand for higher Wi-Fi bandwidth, connectivity and performance everywhere in the home. A modern smart home is best served with an Artificial Intelligence based Internet of Things (AIoT) solution built on Wi-Fi, such as IRIS. In addition to Wi-Fi, IRIS supports Z-Wave and a state-of-the-art voice command interface, along with a multi-language capable home interface. By adding IRIS to existing home networks, service providers can deliver more value-added smart home services to end users in a very simple manner. IRIS can communicate with existing connected devices in the home network, and control various smart home products while optimizing Wi-Fi coverage at home. Consumers will benefit from all the convenience of controlling smart devices via simple voice command, including streaming video or music, home security, home automation and more.

Key features of IRIS:

  • Smart Mesh Wi-Fi extender
  • AIoT voice command hub to Wi-Fi, Z-Wave, AWS/Infrared enabled devices with 12 built-in languages
  • Wireless whole-home audio system for stereo surround, party mode and announcement mode when multiple IRIS’ are used
  • 4 microphone arrays, beamforming, far field recognition and noise cancellation
  • VoIP soft phone for hands-free calls
  • Portable Wi-Fi and Bluetooth speaker with built-in battery (optional)
  • Easy integration for customized apps

“Wi-Fi is the backbone of the smart home,” said Luke Dang, CEO at Tatung Technology, Inc. “With Quantenna’s expertise in Wi-Fi, we are proud to introduce IRIS to bring AI smarts into connected homes. As more and more IoT home products come to the market, the AI technology inside IRIS is a game changer and can truly connect everything in a smart home.”  

“We are excited to work with Tatung to bring this great new AIoT product to market,” said David Carroll, senior vice president, Worldwide Sales at Quantenna. “Tatung’s IRIS is a remarkable example of an OEM creating a breakthrough smart home network product and adding tremendous value on top of Quantenna’s award-winning Wi-Fi technology.”

Tatung will showcase its latest AIoT product line, including IRIS, at ANGA COM 2019, June 4-6, 2019.

About Quantenna Communications
Quantenna (NASDAQ: QTNA) is a global leader and innovator of high-performance Wi-Fi solutions. Founded in 2006, Quantenna has demonstrated its leadership in Wi-Fi technologies with many industry firsts. Quantenna continues to innovate with the mission to perfect Wi-Fi by establishing benchmarks for speed, range, efficiency and reliability. Quantenna takes a multidimensional approach, from silicon and system to software, and provides total Wi-Fi solutions. For more information, visit www.Quantenna.com.

About Tatung Technology Inc.
Tatung specializes in providing a total solution for set-top box and digital home networking products. Tatung partners with leading chipset solution providers and adopts the latest technologies to provide innovative products. With a strong software background, Tatung has served Tier 1 telecom operators worldwide, delivering high quality hardware with software integration in the past decade. For more information, please visit: www.tti.tv.

Quantenna Media Contact
Sally Chan
+1 669 209 5659
pr@quantenna.com

Tatung Media Contact

Emily Cheng
+886 918 542 580
Emily_cheng@tti.tv

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/6af123f3-ae69-4afa-9bf0-d3b008bc9953

Om GlobeNewswire

GlobeNewswire
GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://globenewswire.com

GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Følg saker fra GlobeNewswire

Registrer deg med din epostadresse under for å få de nyeste sakene fra GlobeNewswire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra GlobeNewswire

Apellis Pharmaceuticals Presents Data from Ongoing APL-2 Phase 2 Study in Patients with Cold Agglutinin Disease and Warm Antibody Autoimmune Hemolytic Anemia at 24th European Hematology Association (EHA) Congress15.6.2019 16:00:00 CESTPressemelding

CRESTWOOD, Ky. and WALTHAM Mass., June 15, 2019 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals Inc. (Nasdaq:APLS), a clinical-stage biopharmaceutical company focused on the development of novel therapeutic compounds to treat disease through the inhibition of the complement system, today announced updated data from its Phase 2 PLAUDIT study of APL-2 in patients with autoimmune hemolytic anemia (AIHA), including cold agglutinin disease (CAD) and warm antibody autoimmune hemolytic anemia (wAIHA). Data from the PLAUDIT trial will be presented in an oral presentation today at the 24th Annual Congress of the European Hematology Association (EHA), held in Amsterdam, the Netherlands. In the ongoing PLAUDIT study, 13 patients with CAD have been enrolled to receive subcutaneous APL-2 treatment, of which 10 patients have been on APL-2 for at least 168 days. The trial has also enrolled 11 patients with wAIHA, 8 of which were Direct Antiglobulin Test (DAT) C3+ (C3+ wAIHA); 5 of the C3+ wAIHA patients

Carpenter Technology and BMT Aerospace Combine Expertise in Redesign and Production of Additively Manufactured Aerospace Component14.6.2019 15:17:00 CESTPressemelding

LE BOURGET, France, June 14, 2019 (GLOBE NEWSWIRE) -- Carpenter Technology Corporation (NYSE:CRS) and Belgium-based BMT Aerospace today announced their cooperation in the development of an additively manufactured (AM) aerospace pinion, using Carpenter Technology’s Custom 465® Stainless. BMT Aerospace and its subsidiary BMT Additive initiated the project by partnering with Carpenter Technology to produce a redesigned pinion. The redesign project was initiated to enable the benefits of additive manufacturing using high quality, printable material that would attain the high-performance expectations for the application. “BMT Aerospace strongly believes in the disruptive potential of additive manufacturing and its possibilities in aerospace,” explained Ewald Goossens, Business Unit Manager of BMT Additive. “As a small player in the market, we strongly believe in cooperation opportunities like these, where each partner can rely and build on a project, starting from its own expertise. Our spe

Immunophotonics and Clinical Laserthermia Systems Announce Immuno-Oncology Research Collaboration and Clinical Trials for Cancer Patients with Solid Tumors14.6.2019 13:00:00 CESTPressemelding

Collaboration will Combine Immunophotonics’ Proprietary Drug, IP-001, and CLS’s TRANBERG Laser Thermal Therapy System and imILT Method ST. LOUIS and LUND, Sweden, June 14, 2019 (GLOBE NEWSWIRE) -- Immunophotonics, Inc. and Clinical Laserthermia Systems, AB (STO:CLS B) (CLS) today announced they have entered into a research collaboration agreement to support a Phase 1b/2a clinical trial for cancer patients with certain solid tumor indications. The research will utilize each company’s respective products and methodologies during treatments and is intended to support early phase clinical trials facilitated by a leading clinical organization. Eligible patients with solid tumors will be treated using the locally administered CLS Immunostimulating Interstitial Laser Thermotherapy (imILT) method, followed immediately by an intratumoral injection of Immunophotonics’ lead asset, IP-001. Under the agreement, the CLS TRANBERG Laser and single-use products will be used in eligible patients enrolle

iCAD Introduces ProFound AI™ for 2D Mammography in Europe13.6.2019 14:00:00 CESTPressemelding

Company to showcase its newest artificial intelligence software solution, ProFound AI for 2D Mammography, in addition to ProFound AI for Digital Breast Tomosynthesis at the SIFEM Medical Conference in France NASHUA, N.H. and LILLE, France, June 13, 2019 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced the launch of ProFound AI™ for 2D Mammography in Europe. This software is the latest addition to iCAD’s deep-learning, artificial intelligence platform and follows the launch of ProFound AI™ for Digital Breast Tomosynthesis (DBT), which was CE Marked in March 2018 and FDA cleared in December 2018. ProFound AI for 2D Mammography and ProFound AI for DBT will both be featured in the iCAD exhibition booth (#24) at the Société Française d'Imagerie de la FEMme (SIFEM) medical conference from June 13-15, 2019 at the Grand Palais in Lille, France. “iCAD is at the forefront of the fight ag

Telix Pharmaceuticals and Eczacıbaşı-Monrol Sign Manufacturing and Distribution Agreement13.6.2019 13:54:00 CESTPressemelding

MELBOURNE, Australia and ISTANBUL, Turkey, June 13, 2019 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX.TLX) (“Telix”, the “Company”), a clinical-stage biopharmaceutical company focused on the development of diagnostic and therapeutic products based on targeted radiopharmaceuticals or “molecularly-targeted radiation” (MTR) has today announced that it has concluded a master services and distribution agreement with Eczacıbaşı-Monrol. Under the terms of the agreement, Telix has appointed Eczacıbaşı-Monrol as a radiopharmaceutical production partner and distributor in Turkey/Middle East/North Africa. Eczacıbaşı-Monrol is commercially active in more than 40 countries, including important growth territories that complement Telix’s current commercial strategy for the US and Europe. The parties will initially focus on the production and distribution of TLX250-CDx (89Zr-girentuximab) for imaging of renal cell carcinoma with Positron Emission Tomography (PET), including to support the ad

Highly Accurate Long-Read Sequencing of Human Genomes Leads to Discovery of Disease-Causing Variants13.6.2019 13:30:00 CESTPressemelding

Identification of pathogenic structural variants with SMRT Sequencing improves solve rate for rare and Mendelian diseases MENLO PARK, Calif., June 13, 2019 (GLOBE NEWSWIRE) -- While DNA sequencing tools have been useful for determining the genetic cause of many diseases, there remain a large number that are left unexplained. Recently, scientists have adopted Single Molecule, Real-Time (SMRT®) Sequencing from Pacific Biosciences of California, Inc. (Nasdaq:PACB), a leading provider of high-quality sequencing of genomes, transcriptomes and epigenomes, to study previously unsolved diseases. Many high-impact research publications report expanded variant detection in human genomes, leading to discovery of disease-causing variants and genes underlying rare and Mendelian disorders. In a Nature Communications publication, scientists report that most structural variants (SVs) and large indels are undetected in today’s human genetic studies, which likely accounts for some of the missing heritabi